1. Generics Bulletin
  2. >>Business

Hikma Adds Another Celltrion Biosimilar To MENA Collaboration

Also Launches Pre-Filled Syringe Version Of Naloxone 2mg/2ml In US

 
• By Dave Wallace

Hikma has further expanded its portfolio of biosimilars in the MENA region with the addition of Celltrion’s Vegzelma bevacizumab rival to Avastin. Meanwhile, Hikma has also just launched a new pre-filled syringe version of naloxone in the US.

Celltrion logo on screen with map
Another Celltrion biosimilar has been added to Hikma’s MENA portfolio • Source: Shutterstock

Hikma has added to its partnership with Celltrion in the Middle East and North Africa by striking an exclusive deal to market the Korean firm’s Vegzelma (bevacizumab) biosimilar rival to Avastin in the region.

“Under the terms of the agreement, Celltrion Healthcare will be responsible for the development, manufacturing and supply of Vegzelma and Hikma will be responsible for the commercialization of the product in all its MENA

More from Deals

More from Business